Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis.

By J. Joyce, A. Baruch, K. Chehade, Nicole Meyer-Morse, E. Giraudo, Fong Y. Tsai, D. Greenbaum, J. Hager, M. Bogyo, D. Hanahan. Cancer Cell, 2004

607 citations recorded by the source corpus.

Subfields: Cancer Research, Immunology and Allergy, Rheumatology

View Paper: https://www.semanticscholar.org/paper/711fa29b42ccaa04e877f66e61f577e90c51cfdd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. J. Joyce
2. D. Hanahan
3. G. Bergers
4. D. Hicklin
5. Guido Kroemer
6. B. Turk
7. M. Jäättelä
8. Rakesh K. Jain

In Immunology and Allergy

1. J. Joyce
2. B. Turk
3. G. Bergers
4. D. Hanahan

In Rheumatology

1. J. Joyce
2. D. Hanahan

Citations in the corpus

• Cysteine cathepsins: From structure, function and regulation to new frontiers (2011, background): “creatic islet tumors in a mouse model [346], lacked any efficacy in a mouse breast-cancer model due to the very poor bioavailability of the compound [347].”
• Lysosomes and autophagy in cell death control (2005, background): “More importantly, a broad spectrum inhibitor of cysteine cathepsins impairs the angiogenic switch in pro-genitor lesions as well as impairing growth, vascularity and invasiveness in more advanced tumour”
• Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. (2005, background): “…angiogenic islets and tumors (Parangi et al., 1996), assessing histopathology and vascular morphology (Inoue et al., 2002; Bergers et al., 2003, Joyce et al., 2004) and vascular permeability (Miles and Miles, 1952), isolating constituent cells from tumors (Bergers et al., 2003), and the…”
• IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. (2010, methodology): “Cts B protein can be detected in tumor cells, albeit atmuch lower levels than Cts L, consistent with our previous mRNA expression data from flow cytometrysorted cells (Joyce et al. 2004).”
• Therapeutic targeting of the tumor microenvironment. (2005, positive): “…activator receptor (uPAR) (Hildenbrand et al., 1999), CSF-1 (Lin et al., 2001), MMP-9 (Coussens et al., 2000; Giraudo et al., 2004), cathepsins (Joyce et al., 2004), and heparanase (Joyce et al., 2005); pharmacologic or genetic abla­ tion of these molecules has been shown to significantly…”